Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. jointly announced that the European Commission (EC) has approved the label update of both NILEMDO® (bempedoic acid) and NUSTENDI® (bempedoic acid / ezetimibe fixed-dose combination (FDC)), as treatments for hypercholesterolemia (high levels of cholesterol) and to reduce the risk of adverse ...
read more
Mangoceuticals, Inc. announced the development of proprietary oral formulations of Semaglutide (“Slim”) and Tirzepatide (“Trim”) to aid in weight management. These innovative drugs, currently available predominantly in injectable form, have demonstrated remarkable efficacy in clinical trials.
read more
The Global Pharmaceutical Chemicals Market size is expected to reach $278,760 Million by 2029, growing at a CAGR of 4.9% from 2023 to 2029.
read more
Can-Fite BioPharma Ltd. announced that the FDA granted Investigational New Drug (IND) clearance for Namodenoson, for the treatment of patients with metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), for the Company’s ongoing Phase IIb clinical study.
read more
Cycle Pharmaceuticals Limited announced the launch of ORMALVI™ (dichlorphenamide) tablets, as a treatment option for patients with hyperkalemic periodic paralysis (HyperPP), hypokalemic periodic paralysis (HypoPP) and related variants, approved by the US Food and Drug Administration (FDA).
read more
Centogene N.V. announced the discovery of a new small molecule together with Evotec SE.
read more
CV Sciences, Inc. announced that it has acquired Elevated Softgels, LLC, a manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry. Elevated Softgels has operational flexibility allowing low to large minimum order quantity ("MOQ") production runs, allowing for efficient use of capital and the ability to ...
read more
Avata Biosciences Ltd., the former Sapient Therapeutics, is a clinical-stage biopharmaceutical company with a mission to improve the lives of patients living with neurological diseases. Meaning ‘to unlock’, Avata is emerging with a new name better aligned to unlock the potential of its proprietary technology to treat large patient populations.
read more
Natoli Engineering and TaBlitz have partnered to transform the pharmaceutical landscape by accelerating drug development.
read more
M8 Pharmaceuticals, an Acino company ('M8') announces that the company has signed an exclusive licensing agreement with Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) ('Supernus'), a biopharmaceutical company focused on the development and commercialization of products for the treatment of diseases of the central nervous system (CNS)
read more
Heron Therapeutics, Inc., a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2024 and highlighted recent corporate updates.
read more
PANTHERx®Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by Edenbridge Pharmaceuticals for the distribution of Yargesa® (miglustat) capsules, the first oral treatment option for adults with mild to moderate Type 1 Gaucher disease for whom enzyme replacement...
read more
SK Life Science, Inc., a U.S. pharmaceutical company developing treatments that will change the future of central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals, Co., Ltd., announced the FDA approval of two new
read more
FAonline INC is voluntarily recalling all lots within expiry of the ForeverMen capsules to the consumer level. FDA analysis founds these products to be tainted with sildenafil and Tadalafil.
read more
The drug API Innovation Center announced it has reached a milestone in the development of technology essential to accelerating the U.S. production of lomustine, a critical cancer medication, and will collaborate with St. Louis-based Apertus Pharmaceuticals to expand its manufacturing in Missouri.
read more